Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 8, 2010, Pages 1412-1418

  Zai, Clement C ^a,b   Manchia, Mirko ^a,c   De Luca, Vincenzo ^a,b   Tiwari, Arun K ^a   Squassina, Alessio ^c   Zai, Gwyneth C ^a   Strauss, John ^a   Shaikh, Sajid A ^a   Freeman, Natalie ^a   Meltzer, Herbert Y ^d   Lieberman, Jeffrey ^e   Le Foll, Bernard ^a,b   Kennedy, James L ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d VANDERBILT UNIVERSITY   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Brain derived neurotrophic factor BDNF; Candidate gene association; Dopamine receptor DRD3; Family based association study; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE 3 RECEPTOR; GENOMIC DNA;

ADULT; ALLELE; ARTICLE; BDNF GENE; CASE CONTROL STUDY; CONTROLLED STUDY; DNA ISOLATION; DRD3 GENE; EUROPE; FAMILY STUDY; FEMALE; GENE; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; FAMILY; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D3; RESEARCH DESIGN; SCHIZOPHRENIA;

EID: 78649519116     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.07.019     Document Type: Article

References (62)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
2. Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 2005, 25(26):6251-6259.
3. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21(2):263-265.
4. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 2007, 91:1-5.
5. Chen Z.Y., Patel P.D., Sant G., Meng C.X., Teng K.K., Hempstead B.L., et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wildtype BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004, 24:4401-4411.
6. Costas J., Carrera N., Domínguez E., Vilella E., Martorell L., Valero J., et al. A common haplotype of DRD3 affected by recent positive selection is associated with protection from schizophrenia. Hum Genet 2009, 124(6):607-613.
7. Crocq M.A., Mant R., Asherson P., Williams J., Hode Y., Mayerova A., et al. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 1992, 29(12):858-860.
8. Domínguez E., Loza M.I., Padín F., Gesteira A., Paz E., Páramo M., et al. Extensive linkage disequilibrium mapping at HTR2A and DRD3 for schizophrenia susceptibility genes in the Galician population. Schizophr Res 2007, 90:123-129.
9. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003, 25(2):115-121.
10. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
11. First M.B., Spitzer R.L., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I and II Disorders 1997, American Psychiatric Press, Washington, DC.
12. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007, 420:45-48.
13. Gauderman W.J., Morrison J.M. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies 2006, http://hydra.usc.edu/gxe.
14. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatry Res 2007, 41(1-2):31-35.
15. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411:86-89.
16. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., Joyce J.N. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997, 54(3):225-232.
17. Hodgkinson C.A., Yuan Q., Xu K., Shen P.H., Heinz E., Lobos E.A., et al. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol 2008, 43(5):505-515. Sep-Oct.
18. Hovarth S., Xu X., Laird N.M. The family based association test method: strategies for studying general genotype-phenotype associations. Eur J Hum Genet 2001, 9:304-306.
19. Huang W., Li S., Hu Y., Yu H., Luo F., Zhang Q., Zhu F. Implication of the env gene of the human endogenous retrovirus W family in the expression of BDNF and DRD3 and development of recent-onset schizophrenia. Schizophr Bull 2010, [Jan 25, Electronic publication ahead of print].
20. Ilani T., Ben-Shachar D., Strous R.D., Mazor M., Sheinkman A., Kotler M., et al. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Nat Acad Sci USA 2001, 98(2):625-628.
21. Iritani S., Niizato K., Nawa H., Ikeda K., Emson P.C. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(5):801-807.
22. Ishiguro H., Okuyama Y., Toru M., Arinami T. Mutation and association analysis of the 59 region of the dopamine D3 receptor gene in schizophrenia patients: identification of the Ala38Thr polymorphism and suggested association between DRD3 haplotypes and schizophrenia. Mol Psychiatry 2000, 5:433-438.
23. Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.P., Lucotte G., et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Nat Acad Sci USA 2006, 103(28):10753-10758.
24. Jönsson E.G., Kaiser R., Brockmöller J., Nimgaonkar V.L., Crocq M.-A. Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. Psychiatr Genet 2004, 14:9-12.
25. Kanazawa T., Glatt S.J., Kia-Keating B., Yoneda H., Tsuang M.T. Meta-analysis reveals no association of the Val66Metpolymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr Genet 2007, 17:165-170.
26. Kennedy J.L., Billett E.A., Macciardi F.M., Verga M., Parsons T.J., Meltzer H.Y., et al. Association study of dopamine D3 receptor gene and schizophrenia. Am J Med Genet 1995, 60(6):558-562.
27. Lahiri D.K., Nurnburger J.I. A rapid non-enzymatic method for the preparation of HMV DNA from blood for RFLP analysis. Nucleic Acids Res 1991, 19:5444.
28. Lencz T., Lipsky R.H., DeRosse P., Burdick K.E., Kane J.M., Malhotra A.K. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry 2009, 194(4):313-318. Apr.
29. Lundstrom K., Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest Virus System. Biochem Biophys Res Comm 1996, 225:1068-1072.
30. Ma G., He Z.D., Fang W.L., Tang W., Huang K., Li Z.Q., et al. The Ser9Gly polymorphism of the dopamine D3 receptor gene and risk of schizophrenia: an association study and a large meta-analysis. Schizophr Res 2008, 101:26-35.
31. Mant R., Williams J., Asherson P., Parfitt E., McGuffin P., Owen M.J. Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am J Med Genet 1994, 54(1):21-26.
32. Maxwell E. The family interview for genetic studies: manual. Clinical Neurogenetics Branch, Intramural Research Program 1992, National Institute of Mental Health, Washington, DC, (http:zork.wustl.edunimhfigsfigs_train.pdf).
33. McGuffin P., Farmer A.E., Gottesman I.I., Murray R.M., Reveley A.M. Twin concordance for operationally defined schizophrenia. Confirmation of familiality and heritability. Arch Gen Psychiatry 1984, 41(6):541-545.
34. Muglia P., Vicente A.M., Verga M., King N., Macciardi F., Kennedy J.L. Association between the BDNF gene and schizophrenia. Mol Psychiatry 2003, 8(2):146-147. Feb.
35. Naoe Y., Shinkai T., Hori H., Fukunaka Y., Utsunomiya K., Sakata S., et al. No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: evidence from a case-control study and meta-analysis. Neurosci Lett 2007, 415:108-112.
36. Neves-Pereira N., Cheung J.K., Pasdar A., Zhang F., Breen G., Yates P., et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 2005, 10:208-212.
37. Novak G., LeBlanc M., Zai C., Shaikh S., Renou J., DeLuca V., et al. Association of polymorphisms in the BDNF, DRD1 and DRD3 genes with tobacco smoking in schizophrenia. Annals Hum Genet 2010, 74:291-298.
38. Palomino A., Vallejo-Illarramendi A., González-Pinto A., Aldama A., González-Gómez C., Mosquera F., et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006, 86:321-322.
39. Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., et al. The brain-derived neurotrophic factor Val66Met polymorphism and variation in human cortical morphology. J Neurosci 2004, 24(45):10099-10102.
40. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
41. Qian L., Zhao J., Shi Y., Zhao X., Feng G., Xu F., et al. Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochem Biophys Res Comm 2007, 353:738-743.
42. Renou J., De Luca V., Zai C.C., Bulgin N., Remington G., Meltzer H.Y., et al. Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Mol Psychiatry 2007, 12(12):1058-1060.
43. Schmauss C., Haroutunian V., Davis K.L., Davidson M. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Nat Acad Sci USA 1993, 90:8942-8946.
44. Schmauss C. Enhanced cleavage of an atypical intron of dopamine D3-receptor pre-mRNA in chronic schizophrenia. J Neurosci 1996, 16(24):7902-7909.
45. Schumacher J., Jamra R.A., Becker T., Ohlraun S., Klopp N., Binder E.B., et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 2005, 58:307-314.
46. Shaikh S., Collier D.A., Sham P.C., Ball D., Aitchison K., Vallada H., et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996, 97:714-719.
47. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., et al. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 2003, 351(2):111-114.
48. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460(7256):753-757.
49. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347(6289):146-151.
50. Spurlock G., Williams J., McGuffin P., Aschauer H.N., Lenzinger E., Fuchs K., et al. European multicentre association study of schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms. Am J Med Genet B Neuropsychiatr Genet 1998, 81:24-28.
51. Squassina A., Piccardi P., Del Zompo M., Rossi A., Vita A., Pini S., et al. NRG1 and BDNF genes in schizophrenia: an association study in an Italian case-control sample. Psychiatry Res 2010, 176(1):82-84.
52. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460(7256):744-747.
53. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000, 5:293-300.
54. Talkowski M.E., Mansour H., Chowdari K.V., Wood J., Butler A., Varma P.G., et al. Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples. Biol Psychiatry 2006, 60(6):570-577.
55. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002, 110(3):249-257.
56. Utsunomiya K., Shinkai T., De Luca V., Hwang R., Sakata S., Fukunaka Y., et al. Genetic association between the dopamine D3 gene polymorphism (Ser9Gly) and schizophrenia in Japanese populations: evidence from a case-control study and meta-analysis. Neurosci Lett 2008, 444:161-165.
57. Vogel M., Pfeifer S., Schaub R.T., Grabe H.-J., Barnow S., Freyberger H.J., et al. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 2004, 50:305-310.
58. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003, 8(6):592-610.
59. Xu M.-Q., St Clair D., Ott J., Feng G.-Y., He L. Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis. Schizophr Res 2007, 91:6-13.
60. Zai C., Romano-Silva M.A., Hwang R.W., Zai G.C., deLuca V., Müller D.J., et al. Genetic study of eight AKT1 Gene polymorphisms and their interaction with DRD2 Gene polymorphisms in tardive dyskinesia. Schizophr Res 2008, 106:248-252.
61. Zai C., Tiwari A.K., deLuca V., Müller D.J., Hwang R.W., Zai G., et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009, 19(5):317-328. May.
62. Zintzaras E. Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis. Psychiatr Genet 2007, 17:69-75.